Idorsia Ltd (OTCMKTS:IDRSF) Short Interest Update

Idorsia Ltd (OTCMKTS:IDRSFGet Free Report) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 10,313,000 shares, a growth of 9.7% from the August 15th total of 9,401,800 shares. Based on an average daily trading volume, of 1,300 shares, the short-interest ratio is presently 7,933.1 days.

Idorsia Price Performance

Idorsia stock remained flat at $4.40 during mid-day trading on Tuesday. The business has a fifty day moving average of $6.77 and a two-hundred day moving average of $8.89. Idorsia has a twelve month low of $4.30 and a twelve month high of $19.14.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Morgan Stanley assumed coverage on shares of Idorsia in a research report on Thursday, June 22nd. They set an “underweight” rating for the company. Citigroup started coverage on shares of Idorsia in a research report on Thursday, July 6th. They issued a “sell” rating for the company. Four equities research analysts have rated the stock with a sell rating and two have given a hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $18.00.

Read Our Latest Stock Analysis on Idorsia

About Idorsia

(Get Free Report)

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Featured Articles

Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with's FREE daily email newsletter.